{"id":207807,"name":"BEONE MEDICINES USA, INC. (FKA BEIGENE USA, INC.)","slug":"beone-medicines-usa-inc-fka-beigene-usa-inc","state":"MA","description":"Biopharmaceutical company.","totalSpending":1430000,"filings":24,"yearlySpending":[{"year":2020,"income":40000},{"year":2021,"income":480000},{"year":2022,"income":420000},{"year":2024,"income":280000},{"year":2025,"income":210000}],"firms":["TIBER CREEK GROUP"],"lobbyists":["JOHN GONZALEZ","JONATHON JONES","ANDREW MCKECHNIE","JAMES HEIMBACH","BRYANT HALL","COREY MALMGREN","DANIEL ZAWITOSKI","MATTHEW LEFFINGWELL"],"issues":["TRD","HCR","MMM","MAN","BUD"],"sampleDescriptions":["Monitoring activities related to trade","Monitoring activities related to drug policy","Monitoring activities related to drug policy.","Monitoring activities related to trade.","Issues relating to Part D pricing reform; Issues relating to Part B pricing reform.","Issues related to pharmaceutical pricing and transparency.","Issues related to drug pricing and reimbursement for prescription drugs related to H.R. 5376 - Build Back Better Act, Subtitle J (Part B and D drug pricing).","Issues related to drug pricing and reimbursement for prescription drugs related to H.R. 5376 - Build Back Better Act, Subtitle J (Part B and D drug pricing); Issues related to Prescription Drug User Fee Reauthorization.","Issues relating to US and international manufacturing.","Issues related to drug pricing and reimbursement for prescription drugs related to H.R. 5376 - Build Back Better Act, Subtitle J (Part B and D drug pricing); Issues related to Prescription Drug User Fee Reauthorization; Issues related to clinical trials.","Issues related to drug pricing and reimbursement for prescription drugs related to H.R. 5376 - Build Back Better Act, Subtitle J (Part B and D drug pricing); Issues related to Prescription Drug User Fee Reauthorization; Issues related to clinical trials. H.R. 6833 Affordable Insulin Now Act (Continuing Resolution Shell); H.R. 7667 - Food and Drug Amendments of 2022; S. 4348 - FDA Safety and Landmark Advancements (FDASLA) Act.H.R.5376 - Inflation Reduction Act of 2022 - Public Law No: 117-169.","Issues related to drug pricing and reimbursement for prescription drugs related to H.R. 5376 - Build Back Better Act, Subtitle J (Part B and D drug pricing). H.R.5376 - Inflation Reduction Act of 2022 - Public Law No: 117-169.","Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to FDA, Consolidated Appropriations Act, 2023 (PL 117-328).","Issues related to drug pricing and reimbursement for prescription drugs related to Build Back Better Act/Inflation Reduction Act (PL 117-169), Subtitle B (Part B and D drug pricing).","Issues related to drug pricing and reimbursement for prescription drugs related to Inflation Reduction Act of 2022 (PL 117-169), Subtitle B (Part B and D drug pricing).","Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to FDA, Consolidated Appropriations Act, 2023 (PL 117-328). Issues related to the implementation of the American Relief Act of 2025 (PL 118-158).","Issues related to drug pricing and reimbursement for prescription drugs related to Inflation Reduction Act of 2022 (PL 117-169), Subtitle B (Part B and D drug pricing). Issues related to the implementation of the American Relief Act of 2025 (PL 118-158).","Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to H.R. 946 - ORPHAN Cures Act.","Issues related to drug pricing and reimbursement for prescription drugs related to the Inflation Reduction Act of 2022 (PL 117-169), Subtitle B (Part B and D drug pricing); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158).","Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act; Issues related to the One Big Beautiful Bill Act (PL 119-21)."],"years":[2020,2021,2022,2024,2025]}